Chromatin-regulating protein

Chromatin-regulating proteins are a diverse group of proteins involved in dynamically modifying chromatin structure to regulate DNA accessibility for transcription, repair, replication, and cell division. They include enzymes that modify histones (such as acetyltransferases, deacetylases, methyltransferases, demethylases), ATP-dependent chromatin remodelers (such as members of the SWI/SNF, ISWI, CHD, and INO80 families), as well as proteins that “read” histone modifications (such as bromodomain, Royal, plant homeodomain, and other “reader” domains). These proteins are key mediators of epigenetic processes and play crucial roles in health and disease, notably cancer, where mutations or aberrant regulation of chromatin proteins drive tumorigenesis and resistance. They are now established as bona fide therapeutic targets, with several small-molecule inhibitors in clinical and preclinical development, particularly for cancer treatment. However, “chromatin proteins” is not a single, specific molecular target but a broad functional class; therefore, its use as a drug target requires further specification to individual protein or family (e.g., “BRD4,” “EZH2,” “HDAC1,” etc.)[1][4][7][8].

Other names

Chromatin-modifying proteinChromatin remodelerChromatin modifierChromatin-associated protein

Inhibition of histone deacetylases (HDACs): alters acetylation status, modulates chromatin accessibility, impacts gene expression Inhibition of histone acetyltransferases (HATs): modulates DNA repair and radiosensitivity Inhibition of methyltransferases (e.g., EZH2, DOT1L): affects histone and chromatin methylation patterns[1][3][7] Disruption of chromatin “reader” proteins (e.g., bromodomain or Royal family): blocks recognition of histone modifications, alters gene transcription[7]